Dr. Maya Chen
Chief Executive Officer
Former regulatory affairs lead at a top-10 global pharma. Maya drives Ascent’s long-term vision and partnerships to accelerate affordable access worldwide.
Global Impact
Unwavering access to affordable, life-saving medicines
We develop and manufacture reliable therapeutics that shorten the distance between scientific breakthroughs and the patients who need them most. Our teams combine regulatory mastery, digital manufacturing, and responsible sourcing to scale treatments without compromise.
Leadership
A multidisciplinary team built for rapid delivery
Our leadership blends experience in formulation science, digital operations, commercialization, and patient advocacy. Together, they champion a culture of safety, integrity, and relentless innovation.
Javier Morales
Head of Digital Manufacturing
Specializing in cGMP automation, Javier orchestrates real-time production monitoring, ensuring each batch exceeds quality expectations.
Dr. Priya Sethi
Chief Scientific Officer
Priya leads R&D with a focus on biosimilars and rare disease therapies, mentoring agile lab squads that translate data into breakthrough molecules.
Aaron Blake
VP, Market Access
Aaron connects health systems and payers with transparent pricing and distribution models that keep treatment accessible without sacrificing speed.
Operations
Digitally harmonized facilities engineered for compliance
Our U.S.-based manufacturing campus blends modular clean rooms, robotics, and a validated digital twin. Every unit operation streams telemetry to ensure flawless execution and audit readiness.
Automated Tableting Suite
Robotic loading, in-line weight checks, and HEPA isolated enclosures keep product purity intact.
Cleanroom Grade C Corridor
Sensor-rich environment logs temperature, humidity, and particulate counts to our central dashboard.
Serialization & Packaging
Cloud-tracked serialization ensures downstream traceability and authenticates every lot shipped.
Continuous quality monitoring
Over 1,200 sensors feed our predictive maintenance models, enabling near-zero downtime and rapid deviation response.
cGMP certified & inspection ready
Separate containment suites, redundant filtration, and validated cleaning protocols exceed FDA and EMA expectations.
Flexible capacity
Modular lines shift from high-volume generics to customized therapies in days—without sacrificing compliance.
Pipeline & Portfolio
Therapeutics advancing patient access
Filter by indication or clinical phase to explore how Ascent delivers reliable, affordable medicines. Our digital release process brings market-ready quality weeks faster than legacy approaches.
AP-317
Targeted oncology therapy leveraging adaptive dosing analytics to reduce toxicity and improve adherence.
AP-482
Inhaled biologic improving pulmonary function for chronic respiratory patients with home delivery support.
AP-205
Enzyme replacement therapy paired with companion diagnostics for ultra-rare metabolic disorders.
AP-121
Low-cost antiretroviral with stabilized shelf life and pooled purchasing programs for emerging markets.
Partnerships
Let’s bring therapies to patients faster
Whether you’re a health system leader, emerging biotech, or policy advocate, our partnership team can design the right engagement model and capacity plan.
24 hrs
Average response time from our collaboration office
+1 (718) 555-2500
Global command center, Holbrook, NY